Home » Stocks » ONCY

Oncolytics Biotech Inc. (ONCY)

Stock Price: $2.65 USD 0.00 (0.00%)
Updated May 12, 2021 4:00 PM EDT - Market closed
Market Cap 145.99M
Revenue (ttm) n/a
Net Income (ttm) -22.51M
Shares Out 54.67M
EPS (ttm) -0.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $2.65
Previous Close $2.65
Change ($) 0.00
Change (%) 0.00%
Day's Open 2.68
Day's Range 2.63 - 2.73
Day's Volume 435,089
52-Week Range 1.52 - 4.83

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO and CALGARY, AB, May 10, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting of Shareholders held on Fri...

2 days ago - PRNewsWire

- AWARE-1 clinical data validate clinical development strategy by confirming pelareorep's anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize wi...

5 days ago - PRNewsWire

Management will also provide its annual corporate update after the conclusion of the meeting SAN DIEGO, Calif. and CALGARY, AB, April 30, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TS...

1 week ago - PRNewsWire

SAN DIEGO and CALGARY, AB, April 29, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract discussing its pancreatic adenocarcinoma trial ...

1 week ago - PRNewsWire

Oncolytics Biotech Inc (NASDAQ: ONCY), together with SOLTI, has announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study evaluating pelareorep plus checkpoint blockade ther...

1 month ago - Benzinga

- Pelareorep and atezolizumab synergize the anti-cancer immune response in HR+/HER2- breast cancer patients - Pelareorep alone and with checkpoint blockade converts tumors to PD-L1 positive classificati...

1 month ago - PRNewsWire

SAN DIEGO and CALGARY, AB, April 12, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) recently announced preclinical data highlighting pelareorep's ability to synergize with multi...

1 month ago - PRNewsWire

SAN DIEGO and CALGARY, Alberta, April 8, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, the Company's President and Chief Executive Officer...

1 month ago - PRNewsWire

SAN DIEGO and CALGARY, AB, April 5, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a Key Opinion Leader (KOL) webinar discussing AWARE-1 data, ...

1 month ago - PRNewsWire

Oncolytics Biotech (ONCY) has moved higher as of late, but there could definitely be trouble on the horizon for this company

1 month ago - Zacks Investment Research

SAN DIEGO and CALGARY, AB, March 10, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will present updated clinical data from its AWARE-1 window-of-opportu...

2 months ago - PRNewsWire

SAN DIEGO, Calif. and CALGARY, AB, March 5, 2021 /PRNewswire/ ---- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus,...

2 months ago - PRNewsWire

- New clinical data highlight pelareorep's potential to boost the effectiveness of checkpoint inhibitors - Clinical demonstration of pelareorep reversing immunosuppressive tumor microenvironments - On t...

2 months ago - PRNewsWire

SAN DIEGO, Calif. and CALGARY, AB, Feb. 26, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, March 5, 20...

2 months ago - PRNewsWire

iBio (NYSE: IBIO) shares are trading lower Wednesday after the company reported second-quarter earnings results. iBio's main area of business is plant-based protein expression technologies for vaccines ...

Other stocks mentioned: BHC, DMAC, IBIO, OTLK
2 months ago - Benzinga

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 817 13F filings ...

5 months ago - Insider Monkey

Oncolytics Biotech Inc. (ONCY) CEO Matt Coffey on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

SAN DIEGO, and CALGARY, AB, Nov. 11, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter ended Septem...

6 months ago - PRNewsWire

- Conference call and webcast to take place on Wednesday, November 11, 2020 at 5:00 pm ET SAN DIEGO and CALGARY, AB, Nov. 6, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today...

6 months ago - PRNewsWire

SAN DIEGO and CALGARY, Alberta, Sept. 1, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc.

8 months ago - PRNewsWire

Oncolytics Biotech Inc. (ONCY) CEO Matt Coffey on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

SAN DIEGO and CALGARY, Alberta, June 25, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced a new investigator-sponsored triple-negative breast cancer (TNBC) study ...

10 months ago - PRNewsWire

SAN DIEGO, Calif. and CALGARY, Alberta, June 15, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic vir...

10 months ago - PRNewsWire

SAN DIEGO, California and CALGARY, Alberta, June 4, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today provided a recap of a Key Opinion Leader (KOL) call sponsored by Canacc...

11 months ago - PRNewsWire

SAN DIEGO and CALGARY, Alberta, May 29, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today...

11 months ago - PRNewsWire

SAN DIEGO and CALGARY, Alberta, May 26, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today...

11 months ago - PRNewsWire

SAN DIEGO and CALGARY, Alberta, May 14, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today...

11 months ago - PRNewsWire

Oncolytics Biotech's (ONCY) CEO Matt Coffey on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

During Q4 investors' call, Oncolytics (ONCY) is likely to provide an update on the studies of pelareorep, which is being developed for treating solid tumors and hematological malignancies.

1 year ago - Zacks Investment Research

While travel-related stocks were hit hard on concerns over coronavirus, experimental vaccine companies rallied.

Other stocks mentioned: NVAX
1 year ago - Zacks Investment Research

Oncolytics Biotech: A Small But Very Promising Cancer Player In 2020

1 year ago - Seeking Alpha

As of late, it has definitely been a great time to be an investor in Oncolytics.

1 year ago - Zacks Investment Research

Oncolytics Biotech Inc. (ONCY) CEO Dr.

1 year ago - Seeking Alpha

About ONCY

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-n... [Read more...]

Industry
Biotechnology
IPO Date
Nov 8, 1999
Stock Exchange
NASDAQ
Ticker Symbol
ONCY
Full Company Profile

Financial Performance

Financial Statements